Global Myotonia Congenita Treatment Market, By Type (Becker-Type Myotonia, Thomsen Disease), Treatment (Medication, Physical Therapy, Genetic Counseling, Others), Diagnosis (Blood Tests, Electromyography (EMG), Genetic Testing, Muscle Biopsy, Others), Symptoms (Difficulty swallowing, Gagging, Stiff movements, Shortness of breath, Frequent falls, Difficulty opening eyes, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Myotonia Congenita Treatment Market Analysis and Size
The rise in the prevalence of myotonia congenita is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of myotonia congenita treatment market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness are the factors that will expand the myotonia congenita treatment market. Other factors such as increase in the level of disposable income and growing preference for early genetic counselling will positively impact the myotonia congenita treatment market’s growth rate.
Data Bridge Market Research analyses that the global myotonia congenita treatment market which was USD 874.39 million in 2022, is expected to reach USD 1,895.14 million by 2030, and is expected to undergo a CAGR of 5.4% during the forecast period 2023-2030. This indicates that the market value. “Becker-Type Myotonia” dominates the type segment of the Myotonia Congenita Treatment market owing to the high prevalence of this type of myotonia. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Myotonia Congenita Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Becker-Type Myotonia, Thomsen Disease), Treatment (Medication, Physical Therapy, Genetic Counseling, Others), Diagnosis (Blood Tests, Electromyography (EMG), Genetic Testing, Muscle Biopsy, Others), Symptoms (Difficulty swallowing, Gagging, Stiff movements, Shortness of breath, Frequent falls, Difficulty opening eyes, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Biogen (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), Roche (Switzerland), AbbVie (U.S.), Johnson & Johnson (U.S.), AstraZeneca (U.K.), GlaxoSmithKline (U.K.), Bristol Myers Squibb (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen (U.S.), Eli Lilly and Company (U.S.), Vertex Pharmaceuticals (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Myotonia congenita is a skeletal disorder that affects muscular relaxation and is hereditary. It's congenital, which means its present from the moment you're born. Myotonia congenita (MC) is a hereditary neuromuscular channelopathy that causes skeletal muscle relaxation to be delayed after contraction. It commonly manifests in early childhood. Impaired movement, gastrointestinal disturbances, swallowing, and respiratory problems are just a few of the consequences of MC for patients and their families. Myotonia congenita is divided into two types: Becker-type myotonia is the most prevalent variety, while Thomsen disease is a very rare and milder variant.
Myotonia Congenita Treatment Market Dynamics
Drivers
- Improved Diagnostic Tools
Advances in diagnostic techniques, such as genetic testing and molecular analysis, enable more accurate and timely diagnosis of Myotonia Congenita. Early and precise diagnosis allows for targeted treatment strategies and personalized care for affected individuals.
- Research and Development Proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted for the integration of advanced technologies in the healthcare facilities is also bolstering the market growth rate.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Collaboration and Partnerships
Collaboration among researchers, clinicians, patient advocacy groups, and pharmaceutical companies plays a crucial role in driving Myotonia Congenita treatment forward. Partnerships facilitate the sharing of knowledge, resources, and expertise, leading to faster progress in developing effective therapies.
-
Government Investments on Healthcare Infrastructure
The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative market growth opportunities. Also, high return on investments assured by the research activities will also work in the favour of the market.
Restraints/Challenges
- Rising Competition
The global myotonia congenita treatment market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.
-
Lack of Approved Specific Therapies
Currently, there is no specific cure for global myotonia congenita. Treatment mainly focuses on managing symptoms and improving quality of life. The absence of approved disease-modifying therapies poses challenges in providing effective treatment options that can significantly alter the course of the disease.
This global myotonia congenita treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global myotonia congenita treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In December 2022, AMO Pharma Limited ("AMO Pharma"), announced the completion of patient enrollment in the company's REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy
- In August 2021, AMO Pharma has been working on developing treatments for various rare neuromuscular disorders, including Myotonia Congenita. The company has been involved in clinical trials to evaluate the potential of their investigational drugs in improving muscle function and reducing symptom severity in patients with Myotonia Congenita
Global Myotonia Congenita Treatment Market Scope
The global myotonia congenita treatment market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Becker-Type Myotonia
- Thomsen Disease
Treatment
- Medication
- Sodium Channel Blocking Drugs
- Muscle Relaxants
- Antimalarial Drugs
- Antihistamines
- Anticonvulsant Drugs
- Physical Therapy
- Genetic Counselling
- Others
Diagnosis
- Blood Tests
- Electromyography (EMG)
- Genetic Testing
- Muscle Biopsy
- Others
Symptoms
- Difficulty swallowing
- Gagging
- Stiff movements
- Shortness of breath
- Frequent falls
- Difficulty opening eyes
- Others
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Myotonia Congenita Treatment Market Regional Analysis/Insights
The global myotonia congenita treatment market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global myotonia congenita treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global myotonia congenita treatment market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Myotonia Congenita Treatment Market Share Analysis
The global myotonia congenita treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global myotonia congenita Treatment market.
Some of the major players operating in the global myotonia congenita treatment market are:
- Biogen (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- Roche (Switzerland)
- AbbVie (U.S.)
- Johnson & Johnson (U.S.)
- AstraZeneca (U.K.)
- GlaxoSmithKline (U.K.)
- Bristol Myers Squibb (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Amgen (U.S.)
- Eli Lilly and Company (U.S.)
- Vertex Pharmaceuticals (U.S.)
SKU-